BSE Live
Apr 17, 16:01Prev. Close
156.60
Open Price
158.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Cash Flow of Vikram Thermo India (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 18.48 | 34.06 | 23.04 | 11.77 | 15.99 | |
| Net CashFlow From Operating Activities | 23.64 | 23.20 | 13.05 | 6.04 | 14.85 | |
| Net Cash Used In Investing Activities | -22.40 | -9.44 | -12.63 | -7.46 | -19.36 | |
| Net Cash Used From Financing Activities | -3.96 | -14.19 | 1.49 | 2.66 | 3.15 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -2.72 | -0.42 | 1.92 | 1.24 | -1.36 | |
| Cash And Cash Equivalents Begin of Year | 2.88 | 3.30 | 1.38 | 0.15 | 1.51 | |
| Cash And Cash Equivalents End Of Year | 0.16 | 2.88 | 3.30 | 1.38 | 0.15 |
19.02.2026
Vikram Thermo Standalone December 2025 Net Sales at Rs 34.02 crore, down 0.88% Y-o-Y
12.11.2025
Vikram Thermo Standalone September 2025 Net Sales at Rs 34.64 crore, up 2.9% Y-o-Y
09.09.2025
Vikram Thermo Standalone June 2025 Net Sales at Rs 28.60 crore, down 8.16% Y-o-Y
27.05.2025
Vikram Thermo Standalone March 2025 Net Sales at Rs 27.11 crore, down 13.86% Y-o-Y
19.02.2026
Vikram Thermo Standalone December 2025 Net Sales at Rs 34.02 crore, down 0.88% Y-o-Y
12.11.2025
Vikram Thermo Standalone September 2025 Net Sales at Rs 34.64 crore, up 2.9% Y-o-Y
09.09.2025
Vikram Thermo Standalone June 2025 Net Sales at Rs 28.60 crore, down 8.16% Y-o-Y
27.05.2025
Vikram Thermo Standalone March 2025 Net Sales at Rs 27.11 crore, down 13.86% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth